(WELL) Welltower - Overview
Sector: Real EstateIndustry: REIT - Healthcare Facilities | Exchange NYSE (USA) | Currency USD | Market Cap: 137.269m | Total Return 32.8% in 12m
Stock: Senior Housing, Wellness Communities, Rental Properties
Total Rating 58
Risk 63
Buy Signal -0.40
| Risk 5d forecast | |
|---|---|
| Volatility | 20.0% |
| Relative Tail Risk | -1.41% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.24 |
| Alpha | 27.88 |
| Character TTM | |
|---|---|
| Beta | 0.081 |
| Beta Downside | 0.035 |
| Drawdowns 3y | |
|---|---|
| Max DD | 12.99% |
| CAGR/Max DD | 3.34 |
EPS (Earnings per Share)
Revenue
Risks
Fundamental:
P/E ratio: 138.5423
Description: WELL Welltower March 05, 2026
Welltower Inc. (WELL) is an S&P 500 healthcare REIT specializing in senior housing. The company operates over 2,000 senior and wellness housing communities across the United States, United Kingdom, and Canada. This sector benefits from demographic trends, specifically the aging global population.
Welltower emphasizes its operational approach, viewing itself as an operating company within a real estate framework. Its business model focuses on creating vibrant communities for older adults, blending housing with hospitality services. The company utilizes a data science platform and an operating system to drive capital allocation and performance.
Welltower aims for long-term per-share growth through its disciplined investment strategy and operational efficiency. Further research on ValueRay can provide detailed financial metrics and performance trends for Welltower.
Headlines to watch out for
- Senior housing occupancy rates directly impact rental income
- Interest rate fluctuations influence borrowing costs and property valuations
- Healthcare policy changes affect senior care demand and facility utilization
- Labor shortages in senior care facilities increase operating expenses
- Economic downturns reduce discretionary spending on senior living
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: 936.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.08 > 1.0 |
| NWC/Revenue: 75.53% < 20% (prev 74.60%; Δ 0.92% < -1%) |
| CFO/TA 0.04 > 3% & CFO 2.88b > Net Income 936.8m |
| Net Debt (16.35b) to EBITDA (2.31b): 7.08 < 3 |
| Current Ratio: 5.34 > 1.5 & < 3 |
| Outstanding Shares: last quarter (710.2m) vs 12m ago 11.97% < -2% |
| Gross Margin: 39.18% > 18% (prev 0.38%; Δ 3.88k% > 0.5%) |
| Asset Turnover: 18.03% > 50% (prev 15.39%; Δ 2.64% > 0%) |
| Interest Coverage Ratio: 0.26 > 6 (EBITDA TTM 2.31b / Interest Expense TTM 652.0m) |
Altman Z'' -0.02
| A: 0.12 (Total Current Assets 9.91b - Total Current Liabilities 1.86b) / Total Assets 67.30b |
| B: -0.14 (Retained Earnings -9.16b / Total Assets 67.30b) |
| C: 0.00 (EBIT TTM 171.9m / Avg Total Assets 59.17b) |
| D: -0.36 (Book Value of Equity -8.75b / Total Liabilities 24.10b) |
| Altman-Z'' Score: -0.02 = B |
Beneish M -2.84
| DSRI: 0.98 (Receivables 4.70b/3.52b, Revenue 10.67b/7.85b) |
| GMI: 0.98 (GM 39.18% / 38.50%) |
| AQI: 0.98 (AQ_t 0.82 / AQ_t-1 0.83) |
| SGI: 1.36 (Revenue 10.67b / 7.85b) |
| TATA: -0.03 (NI 936.8m - CFO 2.88b) / TA 67.30b) |
| Beneish M-Score: -2.84 (Cap -4..+1) = A |
What is the price of WELL shares?
As of March 28, 2026, the stock is trading at USD 195.77 with a total of 2,191,063 shares traded.
Over the past week, the price has changed by -0.09%, over one month by -5.48%, over three months by +3.60% and over the past year by +32.75%.
Over the past week, the price has changed by -0.09%, over one month by -5.48%, over three months by +3.60% and over the past year by +32.75%.
Is WELL a buy, sell or hold?
Welltower has received a consensus analysts rating of 4.30.
Therefore, it is recommended to buy WELL.
- StrongBuy: 10
- Buy: 6
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the WELL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 228.8 | 16.9% |
| Analysts Target Price | 228.8 | 16.9% |
WELL Fundamental Data Overview March 27, 2026
P/E Trailing = 138.5423
P/E Forward = 84.7458
P/S = 12.6655
P/B = 3.2583
P/EG = 3.6218
Revenue TTM = 10.67b USD
EBIT TTM = 171.9m USD
EBITDA TTM = 2.31b USD
Long Term Debt = 19.20b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 21.38b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 16.35b USD (from netDebt column, last quarter)
Enterprise Value = 153.62b USD (137.27b + Debt 21.38b - CCE 5.03b)
Interest Coverage Ratio = 0.26 (Ebit TTM 171.9m / Interest Expense TTM 652.0m)
EV/FCF = 53.94x (Enterprise Value 153.62b / FCF TTM 2.85b)
FCF Yield = 1.85% (FCF TTM 2.85b / Enterprise Value 153.62b)
FCF Margin = 26.70% (FCF TTM 2.85b / Revenue TTM 10.67b)
Net Margin = 8.78% (Net Income TTM 936.8m / Revenue TTM 10.67b)
Gross Margin = 39.18% ((Revenue TTM 10.67b - Cost of Revenue TTM 6.49b) / Revenue TTM)
Gross Margin QoQ = 38.30% (prev 39.99%)
Tobins Q-Ratio = 2.28 (Enterprise Value 153.62b / Total Assets 67.30b)
Interest Expense / Debt = 0.95% (Interest Expense 203.8m / Debt 21.38b)
Taxrate = 21.0% (US default 21%)
NOPAT = 135.8m (EBIT 171.9m * (1 - 21.00%))
Current Ratio = 5.34 (Total Current Assets 9.91b / Total Current Liabilities 1.86b)
Debt / Equity = 0.51 (Debt 21.38b / totalStockholderEquity, last quarter 42.13b)
Debt / EBITDA = 7.08 (Net Debt 16.35b / EBITDA 2.31b)
Debt / FCF = 5.74 (Net Debt 16.35b / FCF TTM 2.85b)
Total Stockholder Equity = 37.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.58% (Net Income 936.8m / Total Assets 67.30b)
RoE = 2.49% (Net Income TTM 936.8m / Total Stockholder Equity 37.69b)
RoCE = 0.30% (EBIT 171.9m / Capital Employed (Equity 37.69b + L.T.Debt 19.20b))
RoIC = 0.25% (NOPAT 135.8m / Invested Capital 54.62b)
WACC = 5.53% (E(137.27b)/V(158.65b) * Re(6.27%) + D(21.38b)/V(158.65b) * Rd(0.95%) * (1-Tc(0.21)))
Discount Rate = 6.27% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 13.39%
[DCF] Terminal Value 88.44% ; FCFF base≈2.59b ; Y1≈3.19b ; Y5≈5.45b
[DCF] Fair Price = 203.1 (EV 158.03b - Net Debt 16.35b = Equity 141.68b / Shares 697.8m; r=6.0% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 78.91 | EPS CAGR: 43.91% | SUE: 0.07 | # QB: 0
Revenue Correlation: 97.13 | Revenue CAGR: 24.22% | SUE: 3.22 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.62 | Chg7d=+0.025 | Chg30d=+0.625 | Revisions Net=+0 | Analysts=2
EPS current Year (2026-12-31): EPS=2.47 | Chg7d=+0.000 | Chg30d=+0.010 | Revisions Net=+1 | Growth EPS=+0.0% | Growth Revenue=+26.1%
EPS next Year (2027-12-31): EPS=3.29 | Chg7d=+0.000 | Chg30d=-0.020 | Revisions Net=+1 | Growth EPS=+33.2% | Growth Revenue=+12.5%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 7.2% (Discount Rate 7.9% - Earnings Yield 0.7%)
[Growth] Growth Spread = +23.3% (Analyst 30.5% - Implied 7.2%)
P/E Forward = 84.7458
P/S = 12.6655
P/B = 3.2583
P/EG = 3.6218
Revenue TTM = 10.67b USD
EBIT TTM = 171.9m USD
EBITDA TTM = 2.31b USD
Long Term Debt = 19.20b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 21.38b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 16.35b USD (from netDebt column, last quarter)
Enterprise Value = 153.62b USD (137.27b + Debt 21.38b - CCE 5.03b)
Interest Coverage Ratio = 0.26 (Ebit TTM 171.9m / Interest Expense TTM 652.0m)
EV/FCF = 53.94x (Enterprise Value 153.62b / FCF TTM 2.85b)
FCF Yield = 1.85% (FCF TTM 2.85b / Enterprise Value 153.62b)
FCF Margin = 26.70% (FCF TTM 2.85b / Revenue TTM 10.67b)
Net Margin = 8.78% (Net Income TTM 936.8m / Revenue TTM 10.67b)
Gross Margin = 39.18% ((Revenue TTM 10.67b - Cost of Revenue TTM 6.49b) / Revenue TTM)
Gross Margin QoQ = 38.30% (prev 39.99%)
Tobins Q-Ratio = 2.28 (Enterprise Value 153.62b / Total Assets 67.30b)
Interest Expense / Debt = 0.95% (Interest Expense 203.8m / Debt 21.38b)
Taxrate = 21.0% (US default 21%)
NOPAT = 135.8m (EBIT 171.9m * (1 - 21.00%))
Current Ratio = 5.34 (Total Current Assets 9.91b / Total Current Liabilities 1.86b)
Debt / Equity = 0.51 (Debt 21.38b / totalStockholderEquity, last quarter 42.13b)
Debt / EBITDA = 7.08 (Net Debt 16.35b / EBITDA 2.31b)
Debt / FCF = 5.74 (Net Debt 16.35b / FCF TTM 2.85b)
Total Stockholder Equity = 37.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.58% (Net Income 936.8m / Total Assets 67.30b)
RoE = 2.49% (Net Income TTM 936.8m / Total Stockholder Equity 37.69b)
RoCE = 0.30% (EBIT 171.9m / Capital Employed (Equity 37.69b + L.T.Debt 19.20b))
RoIC = 0.25% (NOPAT 135.8m / Invested Capital 54.62b)
WACC = 5.53% (E(137.27b)/V(158.65b) * Re(6.27%) + D(21.38b)/V(158.65b) * Rd(0.95%) * (1-Tc(0.21)))
Discount Rate = 6.27% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 13.39%
[DCF] Terminal Value 88.44% ; FCFF base≈2.59b ; Y1≈3.19b ; Y5≈5.45b
[DCF] Fair Price = 203.1 (EV 158.03b - Net Debt 16.35b = Equity 141.68b / Shares 697.8m; r=6.0% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 78.91 | EPS CAGR: 43.91% | SUE: 0.07 | # QB: 0
Revenue Correlation: 97.13 | Revenue CAGR: 24.22% | SUE: 3.22 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.62 | Chg7d=+0.025 | Chg30d=+0.625 | Revisions Net=+0 | Analysts=2
EPS current Year (2026-12-31): EPS=2.47 | Chg7d=+0.000 | Chg30d=+0.010 | Revisions Net=+1 | Growth EPS=+0.0% | Growth Revenue=+26.1%
EPS next Year (2027-12-31): EPS=3.29 | Chg7d=+0.000 | Chg30d=-0.020 | Revisions Net=+1 | Growth EPS=+33.2% | Growth Revenue=+12.5%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 7.2% (Discount Rate 7.9% - Earnings Yield 0.7%)
[Growth] Growth Spread = +23.3% (Analyst 30.5% - Implied 7.2%)